A large Danish registry study suggests that adults who start semaglutide for weight management may use fewer triptans — but the effect appears to be driven mainly by women.
Study overview
Researchers from the University of Southern Denmark, in collaboration with Novo Nordisk, analyzed national prescription and health registry data for people who began semaglutide treatment between December 1, 2022, and June 30, 2024. Nearly 150,000 adults who initiated the drug during that period were included; about two-thirds were female. For each person the team tracked triptan prescriptions (a common class of acute migraine medications) for two years before semaglutide start and for one year afterward, measuring monthly use in defined daily doses.
Key findings
– Overall, roughly 4.6% of the cohort filled triptan prescriptions during the study window.
– Triptan use had been rising before semaglutide initiation, but that upward trend reversed afterwards and fell gradually over the following year.
– The decline was most evident among people who were already taking triptans prior to starting semaglutide; there was no meaningful change in the number of new triptan users, suggesting semaglutide didn’t prevent new migraine diagnoses during the study period.
– Sex differences were notable: females showed about an 8% reduction in triptan use after beginning semaglutide, while males showed no statistically significant change.
– Reductions were largest in younger adults (ages 18–35) and in people who had previously used preventive migraine medications.
– The decrease in triptan consumption developed slowly over months rather than immediately after treatment began.
Context and limitations
The findings were presented at the European Congress on Obesity (ECO2026) and have not yet appeared in a peer-reviewed journal. The observational design and reliance on prescription records mean the study can show associations but not prove that semaglutide directly reduces migraine frequency or severity. Changes in healthcare-seeking behavior, prescribing patterns, or other unmeasured factors could influence prescription trends.
Possible explanations
Experts who reviewed the data offered several plausible mechanisms linking GLP-1 receptor agonists like semaglutide to reduced migraine burden:
– Anti-inflammatory effects: GLP-1 drugs can lower systemic and neuroinflammation, and neuroinflammation is implicated in migraine pathophysiology.
– Weight loss and intracranial pressure: Gradual weight reduction that often follows semaglutide use may lower intracranial pressure, which can improve certain headache disorders.
– Direct neural effects: GLP-1 activity influences brain regions involved in migraine signaling — including hypothalamic and brainstem centers — which could alter pain pathways, hormonal regulation, and related neurologic processes.
Sex-specific factors
Researchers and clinicians noted several reasons why women might show a clearer benefit in prescription data: females often achieve greater relative weight loss on GLP-1 therapy, migraine is more prevalent in women to begin with, and sex differences in hormones, immune signaling, fat distribution, and sensitivity of migraine-related pathways (for example the CGRP system) could modify how metabolic and inflammatory improvements translate into migraine outcomes.
Clinical implications
Although the reduction in triptan use seen in women was modest, specialists say even small decreases in reliance on acute migraine medications can matter clinically — potentially lowering the risk of medication-overuse headache and improving quality of life. Some clinicians also point out that if GLP-1 agonists improve comorbid conditions linked to migraine (sleep apnea, hypertension, insulin resistance, systemic inflammation), patients might gain broader neurologic and metabolic benefits.
What’s next
The study adds to growing interest in whether GLP-1 receptor agonists have direct or indirect benefits for migraine, but it does not establish semaglutide as a migraine treatment. Randomized controlled trials and further observational work that include clinical headache outcomes (frequency, severity, disability), patient-reported measures, and longer follow-up are needed before changing clinical practice.
Bottom line
In Danish registry data, starting semaglutide was associated with a gradual reduction in triptan prescriptions, driven largely by women and by people with prior triptan use. The result is intriguing and hypothesis-generating, but more rigorous research is required to confirm whether semaglutide meaningfully reduces migraine burden and to clarify the mechanisms behind any benefit.